DiaMedica Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
DiaMedica Therapeutics Inc. (DMAC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $2.57 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-03-30
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2018 was 7.27 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2018-12-31 | 7.27 CAD/shares 10-K · filed 2019-03-19 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $2.57 10-K · filed 2026-03-30 |
| 2024-12-31 | $2.28 10-K · filed 2025-03-17 |
| 2023-12-31 | $2.65 10-K · filed 2024-03-19 |
| 2022-12-31 | $3.14 10-K · filed 2023-03-28 |
| 2021-12-31 | $3.70 10-K · filed 2022-03-14 |
| 2020-12-31 | $4.86 10-K · filed 2021-03-10 |
| 2019-12-31 | $3.94 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |